GlobeNewswire by notified

Systemair organises Capital Markets Day January 17, 2023

Share

Press Release, December 2, 2022

Systemairis organising a capital market day at our Technical Centre in Skinnskatteberg on January 17.

At the capital markets day Systemair will give investors, analysts and financial media an update of the company's strategy with a focus on growth, profitability, sustainability and smart energy-efficient products. The presentations will also show the company's present market conditions and future growth opportunities.

The presentations will be held in English by members of the management team, followed by a question and answer session.

To register, click here: group.systemair.com/cmd2023

For further information contact:

Roland Kasper, CEO, + 46 73 094 40 13

Anders Ulff, CFO, + 46 70 577 40 09

Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, group.systemair.com

Systemair in brief
Systemair is a leading ventilation company with operations in 52 countries in Europe, North America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 9.6 billion in the 2021/22 financial year and today employs approximately 6,800 people. Systemair has reported an operating profit every year since 1974, when the company was founded. Over the past 10 years, growth has averaged 9.4 percent. Systemair helps to improve the indoor climate with the help of energy-efficient and sustainable products that reduce carbon dioxide emissions. Systemair has well-established operations in growth markets. The Group's products are marketed under the Systemair, Frico, Fantech and Menerga brands. Systemair shares have been quoted on the Nasdaq OMX Nordic Exchange in Stockholm since October 2007 and are today traded on the Large Cap List. The Group comprises about 90 companies.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CGFNS International Reaffirms Its Commitment to Combatting Fraud in Nurse Credentialing2.2.2023 16:01:58 CET | Press release

PHILADELPHIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- In the wake of federal charges related to large-scale schemes to sell fake nursing diplomas at some U.S. nursing schools, CGFNS International, a global leader in international credentials evaluation to support health worker mobility, has bolstered its efforts to combat fraud and ensure patient safety through the assessment and authentication of credentials. Leaders at the organization, which has 45 years of experience in evaluating international education credentials for foreign-trained health workers, pointed to the global nursing shortage as a key driver of increased fraud. "CGFNS is actively reviewing whether any of the reports we issued are impacted," said CGFNS President and Chief Executive Officer Dr. Peter Preziosi. "If we find evidence of this, we will move quickly to address it." "An honestly-earned education paired with appropriate clinical experience is a prerequisite for nursing licensure and is absolutely essential to protect

Graid Technology Announces Software Update Targeted at Enhancing Business Continuity for NVMe Deployments2.2.2023 15:00:00 CET | Press release

SupremeRAID™ new high availability feature provides an additional level of business continuity protection coupled with superior overall performance. SANTA CLARA, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Graid Technology, the award-winning data protection provider and developer of the only RAID card to offer customers access to the full performance of NVMe SSDs, is proud to announce its latest software release (V1.3) for SupremeRAID™ SR-1000 and SR-1010. The various enhancements in this release include features and software updates designed to support dual controller high availability along with support for multiple new NVMe SSDs. Among the enhanced features in the new release is a configurable strip size, allowing customers using RAID 0 and RAID 10 to realize even better server performance, a strategic move that continues to position SupremeRAID™ as the performance leader for both random and sequential workloads. "This latest release gives our customers peace of mind knowing that thei

Global Chauffeur Service Blacklane names Cindy Rubbens as Chief People Experience Officer and Gudrun Herrmann as Global Head of Communications2.2.2023 14:45:44 CET | Press release

Rubbens will oversee the continuous scaling of Blacklane while driving growth via learning and development, while Herrmann is tasked with building up an external and internal strategic communications function and co-drive its sustainability efforts. BERLIN, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Global chauffeur service, Blacklane, announced that it has named Cindy Rubbens Chief People Experience Officer (CPXO) and Gudrun Herrmann Global Head of Communications, effective immediately. Both will report to Blacklane CEO and CO-Founder Dr. Jens Wohltorf and will be charged with developing the Talent Attraction and Human Resources as well as Communications respectively during the company’s bid to scale while driving the next phase of growth. In her role as CPXO, Rubbens will support the sustainable development of Blacklane’s crew while the business continues scaling new, industry-leading services and expanding markets. Rubbens will focus on strengthening the Talent Attraction function while assi

Landsbankinn hf.: Financial results of Landsbankinn for 20222.2.2023 14:36:13 CET | Press release

Landsbankinn's net profit in 2022 was ISK 17.0 billion. There was good growth in loans to corporates, ISK 92.0 billion or the equivalent of 10%, having regard for currency changes.Mortgage loans grew by 59.0 billion with demand decreasing in the fourth quarter.ROE in the fourth quarter of 2022 was 8.2%, compared with 10.5% ROE in the same quarter of 2021. ROE in 2022 was 6.3%, despite solid core earnings. The negative impact reducing profitability was mainly a decrease in the fair value of the Bank’s holding in Eyrir Invest hf. The Bank’s target ROE is 10% at a minimum. Operating expenses are stable. Landsbankinn topped the Icelandic Performance Satisfaction Index for banking customers the fourth year in a row. The Bank’s market share in the retail market has never been higher and measures over 40% for the first time. Loans in arrears are at a historic low and loans in arrears were 0.2% at the turn of the year.In 2022, the Bank paid a dividend of ISK 20.5 billion and ISK 14.1 billion i

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference2.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that